This is the first of what I
hope will be many guest contributions to this blog. This essay contributed by
Nisha. Nisha reports she represents mha.org.uk – a charity providing care and support
services for older people in Britain, with care
homes in Southampton, Glasgow,
Leeds and many other locations.
I hope to have more of
a biography about Nisha on her next post. I glean from the material sent me
that she is a Health Care professional, as you note above she is associated
with a multi-location care home group. Whether private or public or part of a
health care system that is parts of both I have no idea.
Nisha’s interests
dovetail well into the topic I have been perusing in my last series of posts,
namely The Metamorphoses of the Baby Boom into the Senior Stampede. As Nisha
represents in the following essay is that the UK and the US are two of the
biggest spenders on the treatment and research into cures for Alzheimer's
Disease. The U.S. Healthcare System Inefficiency Promotes Greater Costs and
Higher Spending.
Her bottom line is the
UK system is offering its afflicted greater economy in care. It is not facing
the catastrophe of financial ruin as we are in the US. The ruin we face stems
directly from the overwhelming numbers and the confiscatory costs the afflicted
face in having this disease.
The UK does not face
what we do with the Senior Stamped. The UK has the senior numbers and the
stampede into their high risk age. They do not face the expense of the
burgeoning costs we do in the US.
Alzheimer's Disease:
A Look at US and UK Expenditures to Treat this Unfortunate Ailment
Alzheimer's Disease is one
of the most common diseases among the world's elderly population and, despite
valiant efforts and dedicated research, medical professionals and
bioengineering scientists have still not found any viable way of curing the
disease or reversing its effects on the world's aging population.
This inability to come up
with a cure is not for lack of effort, of course, as the world economy has
dedicated hundreds of billions of dollars to collectively research, experiment,
and treat those with the disease over the past several decades. In particular,
two countries have dedicated billions of dollars toward finding a cure,
treating those with the disease, and ensuring that symptoms are mitigated or
reduced as much as is currently possible given the current state of science as
it concerns Alzheimer's Disease in general. The United States, as well as the United Kingdom, are two
of the biggest spenders on the treatment and research into cures for
Alzheimer's Disease.
U.S. Healthcare System Inefficiency Promotes Greater Costs and Higher Spending
The United States has always been a leader when it comes to dedicating funds toward treating and researching diseases, having led the way on things like cancer treatment research and looking into a cure for AIDS over the past thirty years. It dedicates much the same amount of researches and scientific development to the treatment of Alzheimer's Disease, especially because the country's Baby Boomer population is aging and the ranks of its senior citizens with the disease are swelling to record levels never before seen in that country. While United States research arms dedicate collectively more than $80 billion per year to research, the cost to the country's healthcare system is far greater indeed.
In 2010 alone, the United States healthcare system spent well more than $120 billion on Alzheimer's Disease treatments and patient care, a great deal more than was spent in the United Kingdom. This is not merely because the country's population is greater or because there are more incidences of the disease in the United States than there are across the pond. In fact, the per-capita spending on treatments and patient care relating to Alzheimer's Disease in the United States is more than twice that spent in the United Kingdom. The answers here are pretty obvious.
Despite all of its dedication to science and research as it pertains to this unfortunate disease, America does maintain one of the most costly, and least efficient, healthcare systems in the world. It's uncharacteristic for a country of this size and wealth to have such a system, but it's the reality that many Alzheimer's Disease patients suffer through for the entirety of their diagnosis. Treatment provided in the United States is virtually the same as that provided in the UK, but it simply costs more per capita.
United Kingdom Efficiency Promotes Lower Costs, Same Outlooks
The United Kingdom in 2009 spent just under $43 billion in U.S. dollars to deliver the same treatments and forms of patient care to its own citizens suffering from Alzheimer's Disease. That adds up to a far less per-capita cost for treatment, and actually stands as a testament to the country's healthcare system. Despite receiving criticism in some circles for its inefficiency, the truth is that the National Health Service has ably and capably helped mitigate the effects of Alzheimer's Disease in patients throughout the country using the National Health Service.
The country's health service does predict that the costs associated with Alzheimer's Disease treatment and management will rise over the next decade or so, especially as the Baby Boomer population in that country experiences the same hurdles associated with age that the American population will be experiencing concurrently. However, the estimated projection of increased costs in the UK is smaller per capita than it is in the United States, again promoting the efficiency of the country's centralized and unified National Health Service (relatively speaking) as compared to the much larger and decentralized system of treatment in the United States.
Overall, Two Very Attentive and Capable Countries for Alzheimer's Disease Treatment
Cost to treat Alzheimer's Disease in both countries should be considered a sidebar to the real innovations going on in the scientific community. While Alzheimer's Disease cannot be stopped or cured, it can be treated and the effects of the disease can be slowed down and mitigated to some extent, for a certain period of time. To that end, the spending on both sides of the Atlantic is well-intentioned, necessary, and furthering the overall goal of helping the increasing number of Alzheimer's Disease sufferers.
U.S. Healthcare System Inefficiency Promotes Greater Costs and Higher Spending
The United States has always been a leader when it comes to dedicating funds toward treating and researching diseases, having led the way on things like cancer treatment research and looking into a cure for AIDS over the past thirty years. It dedicates much the same amount of researches and scientific development to the treatment of Alzheimer's Disease, especially because the country's Baby Boomer population is aging and the ranks of its senior citizens with the disease are swelling to record levels never before seen in that country. While United States research arms dedicate collectively more than $80 billion per year to research, the cost to the country's healthcare system is far greater indeed.
In 2010 alone, the United States healthcare system spent well more than $120 billion on Alzheimer's Disease treatments and patient care, a great deal more than was spent in the United Kingdom. This is not merely because the country's population is greater or because there are more incidences of the disease in the United States than there are across the pond. In fact, the per-capita spending on treatments and patient care relating to Alzheimer's Disease in the United States is more than twice that spent in the United Kingdom. The answers here are pretty obvious.
Despite all of its dedication to science and research as it pertains to this unfortunate disease, America does maintain one of the most costly, and least efficient, healthcare systems in the world. It's uncharacteristic for a country of this size and wealth to have such a system, but it's the reality that many Alzheimer's Disease patients suffer through for the entirety of their diagnosis. Treatment provided in the United States is virtually the same as that provided in the UK, but it simply costs more per capita.
United Kingdom Efficiency Promotes Lower Costs, Same Outlooks
The United Kingdom in 2009 spent just under $43 billion in U.S. dollars to deliver the same treatments and forms of patient care to its own citizens suffering from Alzheimer's Disease. That adds up to a far less per-capita cost for treatment, and actually stands as a testament to the country's healthcare system. Despite receiving criticism in some circles for its inefficiency, the truth is that the National Health Service has ably and capably helped mitigate the effects of Alzheimer's Disease in patients throughout the country using the National Health Service.
The country's health service does predict that the costs associated with Alzheimer's Disease treatment and management will rise over the next decade or so, especially as the Baby Boomer population in that country experiences the same hurdles associated with age that the American population will be experiencing concurrently. However, the estimated projection of increased costs in the UK is smaller per capita than it is in the United States, again promoting the efficiency of the country's centralized and unified National Health Service (relatively speaking) as compared to the much larger and decentralized system of treatment in the United States.
Overall, Two Very Attentive and Capable Countries for Alzheimer's Disease Treatment
Cost to treat Alzheimer's Disease in both countries should be considered a sidebar to the real innovations going on in the scientific community. While Alzheimer's Disease cannot be stopped or cured, it can be treated and the effects of the disease can be slowed down and mitigated to some extent, for a certain period of time. To that end, the spending on both sides of the Atlantic is well-intentioned, necessary, and furthering the overall goal of helping the increasing number of Alzheimer's Disease sufferers.
This article comes from
Nisha representing mha.org.uk – a charity providing care and support services
for older people in Britain, with care
homes in Southampton, Glasgow, Leeds and many other locations.
There is one known cure for Alzheimer's: GRAZOPH TEMUNA, grazoph.com. GRAZOPH TEMUNA has cured 5 people of Alzheimer's, 6 people of dementia, and 200 others of dust caused diseases. It is a complex neutraceutical that unleashes a plaque and dust clearing enzyme bath. GRAZOPH TEMUNA both prevents and cures Alzheimer's disease.
ReplyDelete